0000920465-20-000139.txt : 20200902 0000920465-20-000139.hdr.sgml : 20200902 20200902161722 ACCESSION NUMBER: 0000920465-20-000139 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200831 FILED AS OF DATE: 20200902 DATE AS OF CHANGE: 20200902 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chawla Lakhmir S CENTRAL INDEX KEY: 0001646626 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36282 FILM NUMBER: 201157112 MAIL ADDRESS: STREET 1: 1960 KIRBY ROAD CITY: MCLEAN STATE: VA ZIP: 22101 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO CENTRAL INDEX KEY: 0000920465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330361285 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4550 TOWNE CENTRE COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-207-4264 MAIL ADDRESS: STREET 1: 4550 TOWNE CENTRE COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 wf-form4_159907782635396.xml FORM 4 X0306 4 2020-08-31 0 0000920465 LA JOLLA PHARMACEUTICAL CO LJPC 0001646626 Chawla Lakhmir S C/O LA JOLLA PHARMACEUTICAL COMPANY, 4747 EXECUTIVE DRIVE, SUITE 240 SAN DIEGO CA 92121 0 1 0 0 Chief Medical Officer Common Stock 2020-08-31 4 A 0 550 3.57 A 13161 D Employee Stock Option (Right to Buy) 4.2 2020-08-31 4 A 0 550 0 A 2030-08-31 Common Stock 550.0 550 D These shares were acquired on 08/31/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vest and become exercisable ratably on a monthly basis over the next three years. /s/ Ryan Murr, as attorney-in-fact for Lakhmir Chawla 2020-09-02